For patients with HER2 IHC 1+ and 0, the risk of bone metastasis is significantly higher than that of patients with HER2 IHC 2+, which suggested that patients with HER2 IHC 1+ and 0 should pay more attention to the review and monitoring of bone metastasis. This evidence concerns the gene ERBB2 and bone metastasis.